0001662579-24-000028.txt : 20240308 0001662579-24-000028.hdr.sgml : 20240308 20240308192423 ACCESSION NUMBER: 0001662579-24-000028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240307 FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schick Kelly CENTRAL INDEX KEY: 0001797388 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39567 FILM NUMBER: 24736193 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: C4 Therapeutics, Inc. CENTRAL INDEX KEY: 0001662579 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475617627 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 231-0700 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 wk-form4_1709943848.xml FORM 4 X0508 4 2024-03-07 0 0001662579 C4 Therapeutics, Inc. CCCC 0001797388 Schick Kelly C/O C4 THERAPEUTICS, INC. 490 ARSENAL WAY #120 WATERTOWN MA 02472 0 1 0 0 Chief People Officer 0 Stock Option (Right to Buy) 37.46 2024-03-07 4 D 0 92000 0 D 2031-01-10 Common Stock 92000 0 D Stock Option (Right to Buy) 19 2024-03-07 4 A 0 92000 0 A 2031-01-10 Common Stock 92000 92000 D Stock Option (Right to Buy) 22.71 2024-03-07 4 D 0 78500 0 D 2032-02-13 Common Stock 78500 0 D Stock Option (Right to Buy) 19 2024-03-07 4 A 0 78500 0 A 2032-02-13 Common Stock 78500 78500 D On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. 25% of the shares underlying this option vested and became exercisable on January 11, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. /s/ Jolie M. Siegel, Attorney-in-Fact 2024-03-08